Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

Eli Lilly (NYSE: LLY) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by joining as a defendant, stating it wants to end the “entitlement” some ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for ... [+] health insurers, employers and government health programs who cover it in 2025.

Eli Lilly cut its 2024 revenue guidance, saying demand for its obesity and diabetes drugs had not met its lofty expectations. Eli Lilly expects about $3.5 billion in revenue for its diabetes ...

Such price increases could directly benefit Eli Lilly by boosting sales of its diabetes ... For example, he proposed 25% tariffs on imports from Canada and Mexico, the two biggest trading partners ...

While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...